Accolade, Inc. (NASDAQ:ACCD - Get Free Report) EVP Richard Eskew sold 3,581 shares of the business's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total value of $12,891.60. Following the completion of the sale, the executive vice president now directly owns 62,507 shares in the company, valued at approximately $225,025.20. This represents a 5.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Richard Eskew also recently made the following trade(s):
- On Monday, November 4th, Richard Eskew sold 336 shares of Accolade stock. The stock was sold at an average price of $3.15, for a total value of $1,058.40.
- On Wednesday, October 2nd, Richard Eskew sold 334 shares of Accolade stock. The stock was sold at an average price of $3.70, for a total value of $1,235.80.
Accolade Trading Down 1.1 %
Shares of Accolade stock opened at $3.53 on Thursday. The company has a fifty day moving average of $3.60 and a 200 day moving average of $4.37. Accolade, Inc. has a fifty-two week low of $3.08 and a fifty-two week high of $15.36. The company has a market capitalization of $284.31 million, a P/E ratio of -3.43 and a beta of 2.07. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.72 and a current ratio of 2.72.
After New Years, price goes back up 4,800%
From StocksToTrade | Ad
When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!
Click here to review Tim’s special Holiday offer before it’s too late.
Accolade (NASDAQ:ACCD - Get Free Report) last released its quarterly earnings data on Tuesday, October 8th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.14. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%. The business had revenue of $106.40 million during the quarter, compared to the consensus estimate of $104.87 million. During the same quarter in the prior year, the firm earned ($0.43) EPS. The business's revenue was up 9.8% on a year-over-year basis. On average, sell-side analysts anticipate that Accolade, Inc. will post -0.92 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on the company. Stephens dropped their price target on Accolade from $10.00 to $8.00 and set an "overweight" rating on the stock in a research report on Wednesday, October 9th. Barclays decreased their price objective on shares of Accolade from $5.50 to $5.00 and set an "equal weight" rating for the company in a report on Wednesday, October 9th. Needham & Company LLC reiterated a "buy" rating and set a $8.00 target price on shares of Accolade in a research note on Monday, October 7th. Truist Financial decreased their target price on shares of Accolade from $9.00 to $7.50 and set a "buy" rating for the company in a research note on Wednesday, October 9th. Finally, Wells Fargo & Company decreased their target price on shares of Accolade from $7.00 to $6.00 and set an "equal weight" rating for the company in a research note on Friday, October 11th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Accolade currently has an average rating of "Moderate Buy" and an average target price of $9.04.
Get Our Latest Stock Analysis on Accolade
Institutional Trading of Accolade
Hedge funds have recently made changes to their positions in the business. Mission Creek Capital Partners Inc. purchased a new stake in shares of Accolade during the 3rd quarter valued at about $38,000. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in shares of Accolade during the 3rd quarter valued at about $46,000. SG Americas Securities LLC purchased a new stake in shares of Accolade during the 2nd quarter valued at about $43,000. Wolverine Trading LLC purchased a new stake in Accolade in the 3rd quarter worth about $51,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in Accolade by 15.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,540 shares of the company's stock worth $205,000 after purchasing an additional 2,586 shares during the last quarter. 84.99% of the stock is currently owned by hedge funds and other institutional investors.
About Accolade
(
Get Free Report)
Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
